JPMorgan Chase & Co. Forecasts Strong Price Appreciation for Edwards Lifesciences (NYSE:EW) Stock

Edwards Lifesciences (NYSE:EW) had its target price increased by investment analysts at JPMorgan Chase & Co. from $100.00 to $105.00 in a report released on Friday,Benzinga reports. The firm presently has an “overweight” rating on the medical research company’s stock. JPMorgan Chase & Co.‘s price target would suggest a potential upside of 27.01% from the company’s current price.

EW has been the topic of several other reports. Royal Bank Of Canada raised their price objective on shares of Edwards Lifesciences from $100.00 to $110.00 and gave the stock an “outperform” rating in a research report on Monday, July 13th. Wolfe Research raised shares of Edwards Lifesciences from a “peer perform” rating to an “outperform” rating and set a $92.00 target price for the company in a report on Wednesday, April 1st. Mizuho increased their target price on shares of Edwards Lifesciences from $100.00 to $105.00 and gave the stock an “outperform” rating in a research note on Wednesday, July 15th. Evercore reissued an “outperform” rating and set a $100.00 price target on shares of Edwards Lifesciences in a report on Monday, July 6th. Finally, Leerink Partners upgraded Edwards Lifesciences from a “market perform” rating to an “outperform” rating and set a $101.00 price target on the stock in a research report on Friday. One equities research analyst has rated the stock with a Strong Buy rating, sixteen have given a Buy rating and seven have given a Hold rating to the company’s stock. According to data from MarketBeat, Edwards Lifesciences has a consensus rating of “Moderate Buy” and a consensus target price of $99.55.

Edwards Lifesciences Price Performance

EW stock opened at $82.67 on Friday. The company has a current ratio of 4.42, a quick ratio of 3.63 and a debt-to-equity ratio of 0.06. The company has a market capitalization of $47.60 billion, a P/E ratio of 47.51, a PEG ratio of 2.07 and a beta of 0.86. The business has a 50 day simple moving average of $87.73 and a 200-day simple moving average of $83.88. Edwards Lifesciences has a twelve month low of $72.30 and a twelve month high of $96.29.

Edwards Lifesciences (NYSE:EW) last announced its earnings results on Thursday, July 23rd. The medical research company reported $0.78 EPS for the quarter, beating analysts’ consensus estimates of $0.74 by $0.04. The business had revenue of $1.74 billion for the quarter, compared to analysts’ expectations of $1.70 billion. Edwards Lifesciences had a net margin of 15.43% and a return on equity of 15.85%. The company’s quarterly revenue was up 13.6% on a year-over-year basis. During the same period in the previous year, the company posted $0.67 EPS. Edwards Lifesciences has set its Q3 2026 guidance at 0.710-0.770 EPS and its FY 2026 guidance at 2.950-3.050 EPS. As a group, equities analysts anticipate that Edwards Lifesciences will post 3 EPS for the current year.

Insider Activity at Edwards Lifesciences

In related news, SVP Andrew M. Dahl sold 568 shares of Edwards Lifesciences stock in a transaction on Friday, May 29th. The shares were sold at an average price of $86.08, for a total value of $48,893.44. Following the transaction, the senior vice president directly owned 15,334 shares in the company, valued at $1,319,950.72. This trade represents a 3.57% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, VP Donald E. Bobo, Jr. sold 23,145 shares of the business’s stock in a transaction on Wednesday, May 27th. The shares were sold at an average price of $86.42, for a total transaction of $2,000,190.90. Following the completion of the transaction, the vice president directly owned 98,611 shares in the company, valued at $8,521,962.62. This represents a 19.01% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold a total of 45,577 shares of company stock worth $3,855,527 in the last three months. Insiders own 0.31% of the company’s stock.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently made changes to their positions in the company. Evermay Wealth Management LLC raised its holdings in Edwards Lifesciences by 4.0% during the fourth quarter. Evermay Wealth Management LLC now owns 3,304 shares of the medical research company’s stock worth $282,000 after purchasing an additional 128 shares in the last quarter. Rehmann Capital Advisory Group boosted its holdings in Edwards Lifesciences by 2.1% in the 4th quarter. Rehmann Capital Advisory Group now owns 6,399 shares of the medical research company’s stock valued at $546,000 after purchasing an additional 130 shares in the last quarter. Florida Trust Wealth Management Co increased its position in Edwards Lifesciences by 1.5% during the 4th quarter. Florida Trust Wealth Management Co now owns 8,810 shares of the medical research company’s stock worth $751,000 after purchasing an additional 132 shares during the period. McIlrath & Eck LLC increased its position in Edwards Lifesciences by 14.6% during the 4th quarter. McIlrath & Eck LLC now owns 1,057 shares of the medical research company’s stock worth $90,000 after purchasing an additional 135 shares during the period. Finally, Quadrant Capital Group LLC raised its stake in shares of Edwards Lifesciences by 0.9% during the 4th quarter. Quadrant Capital Group LLC now owns 15,113 shares of the medical research company’s stock worth $1,288,000 after buying an additional 136 shares in the last quarter. 79.46% of the stock is currently owned by institutional investors and hedge funds.

Edwards Lifesciences News Roundup

Here are the key news stories impacting Edwards Lifesciences this week:

• Positive Sentiment: Edwards Lifesciences beat Q2 estimates on both earnings and revenue, with sales rising 13.6% year over year to $1.74 billion, helped by strong demand for heart-valve products and growing adoption of mitral and tricuspid therapies.
• Positive Sentiment: The company raised the low end of its full-year revenue outlook to $6.6 billion-$6.9 billion and also lifted its TAVR growth guidance, signaling management confidence in continued momentum.
• Positive Sentiment: Analysts turned more constructive after the report: JPMorgan raised its price target to $105 and kept an overweight rating, while Leerink upgraded the stock to outperform with a $101 target.
• Positive Sentiment: Commentary from Wall Street framed the quarter as evidence that Edwards remains a top medtech growth story, with its core TAVR franchise and newer structural heart therapies driving the upside.
• Neutral Sentiment: The company’s updated Q3 and full-year EPS guidance was broadly in line with expectations, suggesting the current move is being driven more by sales strength and sentiment than by a major earnings surprise.

About Edwards Lifesciences

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.